GlassScriptPhysician profile
Saima J Ansari
NPI 1841309192
$3,138.50
in general payments reported to CMS, 2019-2025
22 companies · $786 in 2025
The $786 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $298 · 2020: $214 · 2021: $320 · 2022: $486 · 2023: $334 · 2024: $700 · 2025: $786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,741 · Education: $78.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,741.06 |
| Education | $78.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,765.74 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genentech USA, INC. | $233.32 | 2021-2025 | Xolair |
| Genzyme Corporation | $154.15 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $143.65 | 2020-2024 | Hyqvia |
| Grifols USA, LLC | $108.98 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $92.08 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $82.29 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $78.99 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.70 | 2022-2025 | Spiriva Respimat, Stiolto Respimat, Ofev |
| Novartis Pharmaceuticals Corporation | $62.49 | 2022 | |
| Mylan Specialty L.P. | $46.96 | 2019-2023 | Yupelri |
| Janssen Pharmaceuticals, INC | $42.84 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $41.64 | 2019-2024 | Dupixent |
| Pfizer INC. | $33.85 | 2019-2023 | |
| Inogen, INC. | $30.39 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Resmed Corp | $24.78 | 2025 | |
| Pulmonx Corporation | $23.69 | 2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Avadel Cns Pharmaceuticals, LLC | $22.84 | 2024 | Lumryz |
| Astrazeneca Pharmaceuticals LP | $19.87 | 2022 | |
| United Therapeutics Corporation | $19.70 | 2024 | Tyvaso |
| Insmed, INC. | $18.17 | 2019 | |
| Philips North America LLC | $16.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saima Ansari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.